Back

Ellagic acid ameliorates atherosclerosis by targeting the epidermal growth factor receptor

Huang, Y.-W.; Wang, L.-T.; Yin, H.-L.; Hu, D.-D.; Sheng, J.; Wang, X.-J.

2023-09-15 biochemistry
10.1101/2023.09.14.557846 bioRxiv
Show abstract

BACKGROUNDHigh levels of plasma low-density lipoprotein (LDL) are a key risk factor for atherosclerosis. Low-density lipoprotein receptor (LDLR) mediates the degradation of plasma LDL. Therefore, it may be possible to prevent and treat atherosclerosis by increasing the levels of LDLR. The natural polyphenolic compound ellagic acid (EA) has various biological activities. In mice, EA alleviated the progression of atherosclerosis; however, the underlying mechanism remains unclear. METHODSMolecular interaction, cell, and animal experiments were used to explore the role and mechanism of EA in improving atherosclerosis. RESULTSEA binds to the extracellular domain of the epidermal growth factor receptor (EGFR), thus activating the EGFR-extracellular signal-regulated kinase (EGFR-ERK) signaling pathway, stabilizing LDLR mRNA, and promoting the expression of LDLR protein. The development of EA-loaded human serum albumin nanoparticles enabled intravenous administration in animal experiments. CONCLUSIONSThe research verified the in vivo effects of EA on the EGFR-ERK signaling pathway, LDLR levels, and atherosclerosis. EA may assist in the prevention and treatment of atherosclerosis.

Matching journals

The top 15 journals account for 50% of the predicted probability mass.

1
Food & Function
● 13 papers in training set
Top 0.1%
8.0%
Similar papers in this journal
2
PLOS ONE
● 5266 papers in training set
Top 23%
6.9%
Similar papers in this journal
3
Scientific Reports
○ 3612 papers in training set
Top 18%
4.9%
Similar papers in this journal
4
International Journal of Molecular Sciences
○ 494 papers in training set
Top 2%
4.4%
Similar papers in this journal
5
eLife
● 5828 papers in training set
Top 27%
4.4%
Similar papers in this journal
6
Biochemical and Biophysical Research Communications
○ 84 papers in training set
Top 0.2%
4.1%
7
Molecular Therapy - Nucleic Acids
○ 25 papers in training set
Top 0.1%
3.3%
8
ACS Omega
● 105 papers in training set
Top 0.9%
2.4%
9
Pharmaceutics
○ 24 papers in training set
Top 0.2%
2.4%
10
FEBS Open Bio
○ 31 papers in training set
Top 0.2%
2.2%
11
The FASEB Journal
○ 194 papers in training set
Top 2%
1.9%
12
BioMed Research International
○ 28 papers in training set
Top 0.8%
1.8%
13
Food Chemistry
○ 13 papers in training set
Top 0.1%
1.7%
14
Biomedicine & Pharmacotherapy
○ 42 papers in training set
Top 0.7%
1.5%
15
Cells
○ 249 papers in training set
Top 4%
1.4%
50% of probability mass above
16
Molecular Therapy Nucleic Acids
○ 39 papers in training set
Top 0.5%
1.4%
17
Journal of Medicinal Chemistry
● 77 papers in training set
Top 0.6%
1.4%
18
Arteriosclerosis, Thrombosis, and Vascular Biology
○ 71 papers in training set
Top 0.9%
1.4%
19
Materials Today Bio
○ 20 papers in training set
Top 0.5%
1.4%
20
Pharmacological Research
○ 18 papers in training set
Top 0.3%
1.1%
21
Frontiers in Nutrition
○ 24 papers in training set
Top 0.6%
1.1%
22
Acta Pharmaceutica Sinica B
○ 11 papers in training set
Top 0.2%
1.1%
23
Acta Biochimica et Biophysica Sinica
● 23 papers in training set
Top 0.3%
1.1%
24
Life Sciences
○ 27 papers in training set
Top 0.8%
1.1%
25
Heliyon
○ 152 papers in training set
Top 6%
1.0%
26
Small
○ 78 papers in training set
Top 1%
1.0%
27
Journal of the American Heart Association
○ 140 papers in training set
Top 3%
1.0%
28
Advanced Science
○ 286 papers in training set
Top 8%
1.0%
29
Frontiers in Cardiovascular Medicine
○ 53 papers in training set
Top 2%
0.9%
30
The Journal of Pharmacology and Experimental Therapeutics
○ 18 papers in training set
Top 0.4%
0.9%

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.